Loading patent…
OwnerMichael Didriksen, Sandra Willigers +1inventors
InventorsMichael Didriksen, Sandra Willigers, Jørn Arnt
Estimating the term…
The present invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders. In particular the present invention relates to treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors. The present invention also relates to a pharmaceutical composition comprising a serotonin reuptake inhibitor, and a GlyT-1 inhibitor.
A method of treating a disorder selected from depression, anxiety disorders and other affective disorders, eating disorders phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors in a person in need thereof, the method comprising administering to the person a serotonin reuptake inhibitor and a compound which is a GlyT-1 inhibitor.
(canceled)
A method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor in a person comprising administering a serotonin reuptake inhibitor and a compound which is a GlyT-1 inhibitor to the person.
A pharmaceutical composition comprising a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor, and optionally a pharmaceutically acceptable carrier or diluent.
A kit comprising a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor, and optionally a pharmaceutically acceptable carrier or diluent.
(canceled)
Dependencies are inferred from the claim text.